ReviewTheranostics2014
Nanobody: the "magic bullet" for molecular imaging?
Review in Theranostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 1 synthesis or guideline pooled it, 285 citations in OpenAlex.
- Bimodal nanobody agents for cancer imaging and potential intraoperative guidance: a systematic review.Journal of nanobiotechnology · 2026Pooled it
- Detection of HER2 expression usingBreast cancer research : BCR · 2024Trial
- Enhancing the sensitivity of nanobodies through covalent and non-covalent polymerization.RSC advances · 2026Article
- Affinity- and Format-Dependent Pharmacokinetics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Evaluation of albumin-binding PD-L1-targeted VHH for PET imaging in colorectal cancer.American journal of nuclear medicine and molecular imaging · 2026Article
- Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.Polymer science & technology (Washington, D.C.) · 2025Review
- Monoclonal Antibodies: Historical Perspective and Current Trends in Biological Drug Development.International journal of molecular sciences · 2025Review
- Nanobodies: From Discovery to AI-Driven Design.Biology · 2025Review
- Positron Emission Tomography Imaging of the Adaptive Immune System in Cardiovascular Diseases.Chemical & biomedical imaging · 2025Review
- Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization.Journal of nanobiotechnology · 2025Review
- Nanobody engineering: computational modelling and design for biomedical and therapeutic applications.FEBS open bio · 2025Review
- Preclinical evaluation and pilot clinical study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging.Scientific reports · 2024Article
- CD38 as theranostic target in oncology.Journal of translational medicine · 2024Review
- Preclinical research progress in HER2-targeted small-molecule probes for breast cancer.Radiologie (Heidelberg, Germany) · 2024Review
- A Nanobody of PEDV S1 Protein: Screening and Expression inBiomolecules · 2024Article
- Generation and Characterization of Novel Pan-Cancer Anti-uPAR Fluorescent Nanobodies as Tools for Image-Guided Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Single-domain antibodies as therapeutics for solid tumor treatment.Acta pharmaceutica Sinica. B · 2024Review
- Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Molecular imaging involves the non-invasive investigation of biological processes in vivo at the cellular and molecular level, which can play diverse roles in better understanding and treatment of various diseases. Recently, single domain antigen-binding fragments known as 'nanobodies' were bioengineered and tested for molecular imaging applications. Small molecular size (~15 kDa) and suitable configuration of the complementarity determining regions (CDRs) of nanobodies offer many desirable features suitable for imaging applications, such as rapid targeting and fast blood clearance, high solubility, high stability, easy cloning, modular nature, and the capability of binding to cavities and difficult-to-access antigens. Using nanobody-based probes, several imaging techniques such as radionuclide-based, optical and ultrasound have been employed for visualization of target expression in various disease models. This review summarizes the recent developments in the use of nanobody-based probes for molecular imaging applications. The preclinical data reported to date are quite promising, and it is expected that nanobody-based molecular imaging agents will play an important role in the diagnosis and management of various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.